… ne is clinically needed, dosing should be reduced to one quarter (25%) of the usual dose of 6-mercaptopurine or azathioprine and frequent haematologic monitoring should be ensured (see section 4.4).
Patients should be advised to report any signs or symptoms of bone marrow suppression (unexplained bruising or bleeding, sore throat, fever).
Vidarabine (Adenine Arabinoside)
Evidence suggests that the plasma half-life of vidarabine is increased in the presence of allopurinol. When the two products are used concomitantly extra vigilan …
Identical in all 6 labels. Surrounding text shown from Tillomed Laboratories Ltd.
… rine is clinically needed, dosing should bereduced to one quarter (25%) of the usual dose of 6-mercaptopurine or azathioprine and frequent haematologicmonitoring should be ensured (see section 4.4).
Patients should be advised to report any signs or symptoms of bone marrow suppression (unexplained bruising orbleeding, sore throat, fever).
Vidarabine (Adenine Arabinoside)
Evidence suggests that the plasma half-life of vidarabine is increased in the presence of allopurinol. When the two products are used concomitantly extra vigilanc …
Identical in both labels. Surrounding text shown from Amarox Limited.